Robert J Douglas
The quadrivalent human papillomavirus (HPV) vaccine Gardasil was
licensed for use in June 2006. Since its approval more than 26 million
doses of the vaccine have been distributed worldwide. There is
ongoing debate as to the safety of the vaccine, with suggestions of a
link between the vaccine and syncopal events, and the aetiology of
more chronic conditions such as Guillain-Barre syndrome.
A case of subcutaneous emphysema secondary to quadrivalent
HPV vaccination is described, and reported adverse events to
quadrivalent HPV vaccination in both Australia and the United States
On the basis of published peer reviewed literature, and from data
analysis conducted by reputable agencies, the conclusion is drawn
that adverse events are mild and self limiting and quadrivalent HPV
vaccine is safe when administered according to the manufacturer’s
A woman, 21 years of age, presented to a hospital emergency department complaining of a ‘funny feeling’ in the skin overlying the left deltoid muscle, approximately 2 hours after receiving a 0.5 mL intramuscular dose of quadrivalent human papillomavirus (HPV) vaccine (Gardasil). There were no other symptoms.
Download the PDF for the full article.